CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


Normal salineWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (19)


Name (Synonyms) Correlation
drug508 Calcium Channel Blockers Wiki 0.45
drug2515 Thrombomodulin Modified Thrombin Generation Assay (TGA-TM) Wiki 0.45
drug176 Angiotensin receptor blocker Wiki 0.45
drug1650 Norovirus Bivalent (GI.1 / GII.4) Vaccine(middle) Wiki 0.45
drug2507 Thiazide or Thiazide-like diuretics Wiki 0.45
drug1649 Norovirus Bivalent (GI.1 / GII.4) Vaccine(low) Wiki 0.45
drug2024 Random Donor Plasma Wiki 0.45
drug803 ECCO2R Wiki 0.45
drug1648 Norovirus Bivalent (GI.1 / GII.4) Vaccine(high) Wiki 0.45
drug151 Aluminum adjuvant Wiki 0.45
drug2513 Thrombin Generation Assay (TGA) Wiki 0.45
drug652 Convalescent Plasma Transfusion Wiki 0.32
drug2121 SAB-185 Wiki 0.32
drug2413 TAK-788 Wiki 0.26
drug2381 Supportive Care Wiki 0.26
drug53 ACE inhibitor Wiki 0.26
drug1883 Povidone-Iodine Wiki 0.22
drug576 Clazakizumab Wiki 0.20
drug159 Anakinra Wiki 0.17

Correlated MeSH Terms (14)


Name (Synonyms) Correlation
D005759 Gastroenteritis NIH 0.32
D017250 Caliciviridae Infections NIH 0.32
D004211 Disseminated Intravascular Coagulation NIH 0.22
D020141 Hemostatic Disorders NIH 0.13
D001778 Blood Coagulation Disorders NIH 0.13
D006973 Hypertension NIH 0.12
D016638 Critical Illness NIH 0.06
D014777 Virus Diseases NIH 0.05
D055371 Acute Lung Injury NIH 0.04
D012127 Respiratory Distress Syndrome, Newborn NIH 0.04
D012128 Respiratory Distress Syndrome, Adult NIH 0.04
D018352 Coronavirus Infections NIH 0.04
D007239 Infection NIH 0.03
D045169 Severe Acute Respiratory Syndrome NIH 0.02

Correlated HPO Terms (3)


Name (Synonyms) Correlation
HP:0005521 Disseminated intravascular coagulation HPO 0.22
HP:0001928 Abnormality of coagulation HPO 0.13
HP:0000822 Hypertension HPO 0.12

There are 5 clinical trials

Clinical Trials


1 A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody-mediated Rejection in Kidney Transplant Recipients

This trial investigates whether clazakizumab (an anti-interleukin (IL)-6 monoclonal antibody (mAb)) may be beneficial for the treatment of CABMR in recipients of a kidney transplant by inhibiting the production of Donor Specific Antibodies (DSA) and re-shaping T cell alloimmune responses.

NCT03744910 Antibody-mediated Rejection Biological: Clazakizumab Drug: Normal saline

Primary Outcomes

Description: The aim of this study is to follow enrolled participants until 221 occurrences of all-cause allograft loss, defined as return to dialysis, allograft nephrectomy, re-transplantation, eGFR <15 mL/min/1.73 m2 or death from any cause have been observed. The analysis will be a stratified log rank test of the effect of treatment on all-cause composite allograft loss, with stratification factors of dichotomized baseline eGFR (25-45 mL/min/1.73 m2 versus >45-65 mL/min/1.73 m2), baseline proteinuria, treatment for early (within 6 months of transplant) ABMR rejection episodes (yes/no), and treatment for late (greater than 6 months post transplant) ABMR rejection episodes (yes/no). Surviving subjects without allograft loss will be censored at the time of their last assessment.

Measure: Incidence of all cause composite allograft loss

Time: Five years

2 A Randomized, Blind, Placebo-controlled Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant Norovirus Bivalent (GI. 1 / GII. 4) Vaccine (Hansenulapolymorpha) in Healthy People Aged 6 Months to 59 Years

A total of 450 subjects were enrolled, divided into four age groups, including 18-59 years, 6-17 years, 3-5 years, and 6-35 months. There are three types of the test vaccine component in each age group. A total of 30 people in each dose group were vaccinated with the test vaccine or placebo 1 or placebo 2, respectively, in a ratio of 3: 1: 1. The 18-59-year-old, 6-17-year-old, and 3-5-year-old age groups were vaccinated 2 times at a time interval of 28 days. The 6-35 month age group is divided into two groups, Group 1 is inoculated with 2 doses interval of 28 days each, and Group 2 is inoculated with 3 doses interval of 28 days.

NCT04188691 Norwalk Gastroenteritis Norovirus Infections Biological: Norovirus Bivalent (GI.1 / GII.4) Vaccine(low) Biological: Norovirus Bivalent (GI.1 / GII.4) Vaccine(middle) Biological: Norovirus Bivalent (GI.1 / GII.4) Vaccine(high) Biological: Normal saline Biological: Aluminum adjuvant
MeSH:Caliciviridae Infections Gastroenteritis

Primary Outcomes

Measure: AE of local and systemic reactions within 30 minutes after each dose

Time: 30 minutes

Description: Active AE: Local and systemic adverse reactions occurring within 0-7 days after each dose of vaccination

Measure: All active AEs within 0-7 days after each dose

Time: 7 days

Description: Adverse events other than active AE include solicitation adverse events reported in addition to the specified solicitation time window

Measure: All non-active collection AEs within 0-28(30) days after each dose

Time: 28(30) days

Measure: All SAEs within 6 months after the last dose is vaccinated

Time: 6 months

Secondary Outcomes

Measure: Calculate geometric mean titer (GMT) of NoV GI.1 and GII.4 IgG antibodies

Time: 28 days after the full vaccination

Measure: Calculate positive rate of NoV GI.1 and GII.4 IgG antibodies

Time: 28 days after the full vaccination

Measure: Calculate NoV GI.1 and GII.4 HBGA-blocking antibody titers

Time: 28 days after the full vaccination

Measure: Calculate NoV GI.1 and GII.4 HBGA-blocking antibody positive rates

Time: 28 days after the full vaccination

3 Early Identification and Treatment of Cytokine Storm Syndrome in Covid-19

This proposal addresses the problem of preventing the very high mortality and morbidity associated with the development of Cytokine Storm Syndrome (CSS) associated respiratory failure in Covid-19 infection.

NCT04362111 Cytokine Storm COVID-19 Drug: Anakinra Drug: Normal saline

Primary Outcomes

Description: Supplemental oxygen requirement to maintain oxygen saturation >90% stable or decreased without escalation of respiratory measures (addition of CPAP, initiation of mechanical ventilation)

Measure: No increase in oxygen requirement and no increase in respiratory support measures

Time: 48 hours

Secondary Outcomes

Description: 25% decrease in noted baseline elevations of serum ferritin, LDH, CRP, and d-dimer.

Measure: Improvement in Cytokine Storm markers

Time: 72 hours

Description: Subjects discharged from hospital without the need for mechanical ventilation

Measure: No requirement for mechanical ventilation

Time: Day 5 (120 hours)

4 Can a Sinus Rinse and Mouth Wash Reduce Viral Load in COVID-19 Positive Individuals and Their Co-residents?

COVID-19 is highly infectious and transmission of the virus is thought to be similar to that of influenza which can be transferred through droplets released when a person coughs, sneezes or talks. Studies have shown that nasal rinsing and mouth washes may be an important way to deliver treatments that could reduce the amount of a virus that is present in the nose and mouth. This also could mean that there is less virus available to pass on to others. We want to see if the use of nose rinses and mouth washes using Povidone-Iodine will reduce the the amount of virus in the nose and throat of people who have tested positive for COVID-19 disease and also reduce the spread of infection within their household.

NCT04393792 Coronavirus Infection Drug: Povidone-Iodine Drug: Normal saline
MeSH:Coronavirus Infections Severe Acute Respiratory Syndrome

Primary Outcomes

Description: viral load as measured by real time polymerase chain reaction (PCR)

Measure: Change in viral load in the oral and nasopharyngeal cavity

Time: Day 0, 2, 3, 7, 14

Secondary Outcomes

Description: Visual analogue score 1-5 per symptom via a smartphone app

Measure: Symptom severity in primary participants and co-residents

Time: Days 0 to 14

5 A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study of SAB-185 in Healthy Subjects

Coronavirus disease 2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). SAB Biotherapeutics has developed SAB-185, an Anti-SARS-CoV-2 Human Immunoglobulin Intravenous (transchromosomic [Tc] bovine-derived), as a potential therapeutic to treat COVID-19. This study will evaluate the safety, immunogenicity, and pharmacokinetics of SAB-185 in healthy participants.

NCT04468958 COVID-19 SARS-CoV2 Biological: SAB-185 Other: Normal saline

Primary Outcomes

Description: Incidence and severity of other adverse events and severe adverse events (SAE)

Measure: Number of Participants Having Adverse Events

Time: 29 Days

Description: transfusion-related adverse events

Measure: Number of Participants Having Transfusion-Related Adverse Events

Time: 29 Days

Secondary Outcomes

Description: Incidence and severity of adverse events and SAEs from Screening through Study Day 90

Measure: Number of Participants Having Adverse Events

Time: 90 Days

Description: SARS-CoV-2 binding (ELISA) and neutralizing (PRNT80) antibody titers from Screening through Study Day 90

Measure: Pharmacokinetics from screening to day 90

Time: 90 Days


No related HPO nodes (Using clinical trials)